| Ovarian cancer GC Jayson, EC Kohn, HC Kitchener, JA Ledermann The Lancet 384 (9951), 1376-1388, 2014 | 2047 | 2014 |
| Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial S Kehoe, J Hook, M Nankivell, GC Jayson, H Kitchener, T Lopes, ... The Lancet 386 (9990), 249-257, 2015 | 1373 | 2015 |
| Imaging biomarker roadmap for cancer studies JPB O'connor, EO Aboagye, JE Adams, HJWL Aerts, SF Barrington, ... Nature reviews Clinical oncology 14 (3), 169-186, 2017 | 1034 | 2017 |
| Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ... The Lancet Oncology 16 (8), 928-936, 2015 | 884 | 2015 |
| Experimentally‐derived functional form for a population‐averaged high‐temporal‐resolution arterial input function for dynamic contrast‐enhanced MRI GJM Parker, C Roberts, A Macdonald, GA Buonaccorsi, S Cheung, ... Magnetic Resonance in Medicine: An Official Journal of the International …, 2006 | 810 | 2006 |
| Antiangiogenic therapy in oncology: current status and future directions GC Jayson, R Kerbel, LM Ellis, AL Harris The Lancet 388 (10043), 518-529, 2016 | 809 | 2016 |
| Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma PA Vasey, GC Jayson, A Gordon, H Gabra, R Coleman, R Atkinson, ... Journal of the National Cancer Institute 96 (22), 1682-1691, 2004 | 792 | 2004 |
| Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial GJS Rustin, MEL Van Der Burg, CL Griffin, D Guthrie, A Lamont, ... The Lancet 376 (9747), 1155-1163, 2010 | 736 | 2010 |
| DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents JPB O'Connor, A Jackson, GJM Parker, GC Jayson British journal of cancer 96 (2), 189-195, 2007 | 631 | 2007 |
| The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations MO Leach, KM Brindle, JL Evelhoch, JR Griffiths, MR Horsman, A Jackson, ... British journal of cancer 92 (9), 1599-1610, 2005 | 585 | 2005 |
| Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies JPB O'connor, A Jackson, GJM Parker, C Roberts, GC Jayson Nature reviews Clinical oncology 9 (3), 167-177, 2012 | 403 | 2012 |
| Intra-tumoural microvessel density in human solid tumours J Hasan, R Byers, GC Jayson British journal of cancer 86 (10), 1566-1577, 2002 | 399 | 2002 |
| Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging A Jackson, JPB O'Connor, GJM Parker, GC Jayson Clinical Cancer Research 13 (12), 3449-3459, 2007 | 388 | 2007 |
| Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies GC Jayson, J Zweit, A Jackson, C Mulatero, P Julyan, M Ranson, ... Journal of the National Cancer Institute 94 (19), 1484-1493, 2002 | 329 | 2002 |
| Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue AM Wardley, GC Jayson, R Swindell, GR Morgenstern, J Chang, R Bloor, ... British journal of haematology 110 (2), 292-299, 2000 | 293 | 2000 |
| Biomarkers of angiogenesis and their role in the development of VEGF inhibitors N Murukesh, C Dive, GC Jayson British journal of cancer 102 (1), 8-18, 2010 | 274 | 2010 |
| Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial JA Ledermann, AC Embleton, F Raja, TJ Perren, GC Jayson, GJS Rustin, ... The Lancet 387 (10023), 1066-1074, 2016 | 268 | 2016 |
| Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study J Hipkins, M Whitworth, N Tarrier, G Jayson British journal of health psychology 9 (4), 569-581, 2004 | 254 | 2004 |
| Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials I Vergote, C Coens, M Nankivell, GB Kristensen, MKB Parmar, T Ehlen, ... The Lancet Oncology 19 (12), 1680-1687, 2018 | 253 | 2018 |
| Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer JA Ledermann, A Hackshaw, S Kaye, G Jayson, H Gabra, I McNeish, ... J Clin Oncol 29 (28), 3798-3804, 2011 | 245 | 2011 |
